John Seymour, MD, discusses the development and clinical application of BCL-2 inhibitors for the treatment of CLL.

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today ...

It was shown that arginine induced expression of Bcl-2 and Bcl-xL, while rReg4 upregulated Bcl-2 and Bcl-xL expression by activating the EGFR/Akt pathway. The upregulation of Bcl-xL correlated ...

how this is deregulated in diseases such as cancers and exploiting our knowledge of the BCL-2-regulated pathway for developing better therapeutics,” he says. Complementing this research in ...

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today ...

Identification of six cancer susceptibility genes offers new insights into genetic risk factors, potentially enhancing early ...

Results Increased expression of hypoxia-inducible factor 1α, Bcl-2 and clusterin was detected in subscapularis tendon samples compared ... with increased production of collagen type III operating ...

Two leaders of the banned Bangladesh Chhatra League (BCL) of the Dhaka University unit were arrested from the capital city of Dhaka and Narsingdi district for attacking students during the ...

In the wake of recent violent clashes between student protesters and Bangladesh Chhatra League (BCL) activists at Dhaka University, a wave of support from celebrities has emerged for the quota ...

although alternative methods of targeting these pathways may be effective. MEK inhibitors form the backbone of multiple regimens entering clinical trials and are being combined with BCL-XL ...